Dr. Brammer on FDA Approval of Brentuximab Vedotin in CTCL

Jonathan Brammer, MD

Published: Thursday, Nov 09, 2017

Jonathan Brammer, MD, hematologist, Department of Internal Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center, discusses the FDA approval of brentuximab vedotin (Adcetris) for the treatment of patients with cutaneous T-cell lymphoma (CTCL).

SEE ALL VIDEOS FROM: Jonathan Brammer, MD

View more on OncLive TV >>>

Trending Now

Expert Encourages Adjuvant Endocrine Therapy in Premenopausal Breast Cancer

Immunotherapy's Role in TNBC May Be in Combination

Options Continue to Emerge for Transplant-Ineligible Multiple Myeloma

Chemotherapy Remains Critical in NSCLC Paradigm

Lead Author Explains ASCO's Statement on Biosimilars in Oncology

Expert Highlights PARP Inhibitor Advancements in Ovarian Cancer, Points to Future Combos

Brentuximab Vedotin Approved in Europe for CTCL

Expert Highlights Advances in Cutaneous T-Cell Lymphoma

Venetoclax Demonstrates Strong Activity in CLL After BCR Inhibitor

Related Videos

Dr. O'Malley on FDA Approval of Maintenance Rucaparib in Ovarian Cancer

Dr. Moskowitz on the ALCANZA Trial in CTCL

Dr. Byrd Discusses the Future Treatment of CLL

Dr. Backes Discusses PARP Inhibitor Combinations in Ovarian Cancer

View Conference Coverage

2018 AACR Annual Meeting

2018 European Lung Cancer Congress

2018 SGO Annual Meeting

2018 State of the Science Summit on Gastrointestinal Malignancies

Online CME Activities

Title	Expiration Date	CME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better Outcomes	Apr 27, 2018	2.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma	Apr 27, 2018	2.0